Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-29
2008-12-09
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S490000, C548S491000
Reexamination Certificate
active
07462640
ABSTRACT:
The present invention refers to new sulfonamide derivatives, of general formula (Ia, Ib, Ic) optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, at any mixing ratio or their salts, preferably the corresponding, physiologically acceptable salts, or corresponding solvates; to the process for their preparation, to their application as medicaments in human and/or veterinary therapeutics, and to the pharmaceutical compositions containing them.
REFERENCES:
patent: 3472870 (1969-10-01), Larsen et al.
patent: 2003/0191124 (2003-10-01), Merce-Vidal et al.
patent: 2005/0032791 (2005-02-01), Merce-Vidal et al.
patent: 2005/0065202 (2005-03-01), Vidal et al.
patent: 2007/0043041 (2007-02-01), Vidal et al.
patent: 0 733 628 (1996-06-01), None
patent: 0 815 861 (1998-01-01), None
patent: 0 815 961 (1998-01-01), None
patent: WO 95/32967 (1995-12-01), None
patent: WO 01/32646 (2001-05-01), None
patent: 02/060871 (2002-08-01), None
patent: WO 02/066470 (2002-08-01), None
patent: 03/042175 (2003-05-01), None
Liu et al., Psychiatry and clinical neurosciences, 2001, vol. 55, pp. 427-429.
Laconde et al., Journal of enzyme inhibition and medicinal chemistry, 2003, vol. 18, pp. 89-94.
D. Hoyer, et al., Neuropharmacology, vol. 36, No. 4/5, pp. 419-428 (1997).
F.J. Monsma, Jr., et al., Molecular Pharmacology, vol. 43, pp. 320-327 (1993).
M. Ruat, et al., Biochemical and Biophysical Research Communications, vol. 193, No. 1, pp. 268-276 (1993).
R. Kohen, et al., Journal of Neurochemistry, vol. 66, No. 1, pp. 47-56 (1996).
M. Yoshioka, et al., Ann. NY Acad. Sci. vol. 861, pp. 244 (1998).
A.V. Turnbull, et al., Diabetes, vol. 51, pp. 2441-2449 (2002).
A. Bourson, et al., British jurnal of Pharmacology, vol. 125, pp. 1562-1566 (1998).
D.C. Rogers, et al., Br. J. Pharmacol. Supp., vol. 127, pp. 22P (1999).
A. Bourson, et al., J. Pharmacol. Exp. Ther., vol. 274, No. 1, pp. 173-180 (1995).
A.J. Sleight, et al., Behavioural Brain Research, vol. 73, pp. 245-248 (1996).
T.A. Branchek, et al., Annu. Rev. Pharmacol. Toxicol, vol. 40, pp. 319-334 (2000).
C. Routledge, British Journal of Pharmacology, vol. 130, pp. 1606-1612 (2000).
B.L. Roth, et al., J. Pharmacol. Exp. Ther., vol. 268, pp. 1403-1410 (1994).
C.E. Glatt, et al., Molecular Medicine, vol. 1, No. 4, pp. 398-406 (1995).
T. Shinkai, et al., American Journal of Medical Genetics (Neuropsychiatric Genetics), vol. 88, pp. 120-122 (1999).
C. Gerard, et al., Brain Research, vol. 746, pp. 207-219 (1997).
M.R. Pranzatelli, Drugs of Today, vol. 33, No. 6, pp. 379-392 (1997).
E.E. Gilbert, Synthesis-International Journal of Methods in Synthetic Organic Chemistry No. 1, pp. 3-10 (1969).
L.D. Basanagoudar, et al., J. Indian Chem. Soc., vol. 49, No. 8, pp. 811-813 (1972).
S.A. Yamashkin, et al., Chemistry of Heterocyclic Compounds, vol. 35, No. 12, pp. 1426-1432 (1999).
S.R. Boothroyd, et al., Tetrahedron Letters, vol. 36, No. 14, pp. 2411-2414 (1995).
J.E. Macor, et al., Synthetic Communications, vol. 23, No. 1, pp. 65-72 (1993).
M. Macchia, et al., IL. Farmaco, vol. 51, No. 1, pp. 75-78 (1996).
S.S. Bhagwat, et al., Tetrahedron Letters, vol. 35, No. 12, pp. 1847-1850 (1994).
L.D. Bratton, et al., J. Heterocyclic Chem., vol. 37, pp. 1103-1108 (2000).
O. Ottoni, et al., Tetrahedron Letters, vol. 40, pp. 1117-1120 (1999).
S.L. Vorobeva, et al., Khim Geterosiki Soedin (KGSSAQ) (5), pp. 636-637 (1991).
A.R. Katritzky, et al., Org. Prep. Proceed. Inc. (OPPIAK), vol. 23, No. 3, pp. 357-363 (1991).
N. Moskalev, et al., Heterocycles (HTCYAM), vol. 52, No. 2, pp. 533-536 (2000).
P.J. Munson, et al., Analytical Biochemistry, vol. 107, pp. 220-239 (1980).
A. Kask, et al., European Journal of Pharmacology, vol. 414, pp. 215-224 (2001).
“Oral drug deliver, small intestine and colon”, Encyclopedia of Controlled Drug Deliver, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York, vol. 2, 698-728 (1999).
W.D. Hirst, et al., British Journal of Pharmacology, vol 130, pp. 1597-1605 (2000).
M.L. Woolley, et al., Neuropharmacology, vol. 41, pp. 210-219 (2001).
M. Abou-Gharbia, et al., Eur. J. Med. Chem., vol. 23, pp. 373-377 (1988).
K. Yamada, et al., Heterocycles, vol. 55, No. 6, pp. 1151-1159 (2001).
K. Takada, et al., “Oral Drug Delivery”, Encyclopedia of Controlled Drug Deliver, Mathiowiz, E., (ed.), John Wiley and Sons, Inc., New York, vol. 2, pp. 728-742 (1999).
Dictionary of Microbiology and Molecular Biology, Second Edition, Paul Singleton/Diana Sainsbury, pp. 707 and 934.
J.C. Bentley, et al., J. Psychopharmacol., p. A64, Abstract No. 255 (1997).
J.C. Bentley, et al., British Journal of Pharmacology, vol. 126, pp. 1537-1542 (1999).
J. Svartengren, et al., Int. J. Obes, p. 566, Abstract No. T1:P1-094 (2003).
Brown, Frederick J. et al: “Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1, 6-Disubstituted Indoles and Indazoles”, Journal of Medicinal Chemistry, vol. 6 No. 33, pp. 1771-1781, 1990.
Laconde, G. et al., “New Analogues of the Anticancer E7070: Synthesis and Pharmacology”, Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 18, No. 2, pp. 89-94, 2003.
U.S. Appl. No. 11/679,344, filed Feb. 27, 2007, Merce Vidal.
U.S. Appl. No. 11/673,328, filed Feb. 9, 2007, Merce Vidal et al.
Codony Soler Xavier
Dordal Zueras Alberto
Merce Vidal Ramon
Laboratorios del Dr. Esteve S.A.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Indol-6yl sulfonamide derivatives, their preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indol-6yl sulfonamide derivatives, their preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indol-6yl sulfonamide derivatives, their preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024199